Potential new treatment for cocaine addiction

A promising new drug treatment for cocaine addiction has been discovered by researchers. The experimental therapy, which involves administering a drug currently used in cancer therapy trials, treats cocaine addiction by inhibiting memories responsible for cravings.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

Abstract Identification of the genomic drivers of cancer has led to the clinical development of targeted therapies that strike at the heart of many malignancies. Nonetheless, many cancers outsmart such precision-medicine efforts, and thus therapeutic resistance contributes significantly to cancer mortality. Attempts to understand the basis for resistance in patient samples and laboratory models has yielded two major benefits: one, more effective chemical inhibitors and rational combination therapies are now employed to prevent or circumvent resistance pathways; and two, our understanding of how oncogenic mutations...
Source: Trends in Molecular Medicine - Category: Molecular Biology Authors: Tags: Trends Mol Med Source Type: research
Publication date: Available online 13 December 2018Source: Redox BiologyAuthor(s): Matilda Lee, Jayshree L. Hirpara, Jie-Qing Eu, Gautam Sethi, Lingzhi Wang, Boon-Cher Goh, Andrea L. WongAbstractDrug resistance invariably limits the response of oncogene-addicted cancer cells to targeted therapy. The upregulation of signal transducer and activator of transcription 3 (STAT3) has been implicated as a mechanism of drug resistance in a range of oncogene-addicted cancers. However, the development of inhibitors against STAT3 has been fraught with challenges such as poor delivery or lack of specificity. Clinical experience with sm...
Source: Redox Biology - Category: Biology Source Type: research
In this study, we use a multi-scale modeling approach to interrogate the implications of three metabolic scenarios of potential clinical relevance: the Warburg effect, the reverse Warburg effect and glutamine addiction. At the intracellular level, we construct a network of central metabolism and perform flux balance analysis (FBA) to estimate metabolic fluxes; at the cellular level, we exploit this metabolic network to calculate parameters for a coarse-grained description of cellular growth kinetics; an d at the multicellular level, we incorporate these kinetic schemes into the cellular automata of an agent-based model (AB...
Source: PLoS Computational Biology - Category: Biology Authors: Source Type: research
ConclusionsUsing novel selective or dual BCL-2/BCL-xL inhibitor, we probed the oncogene addiction patterns in a panel of hematologic malignancy cell lines, and revealed a mix pattern of dependence on BCL-2, BCL-xL or MCL-1. The BCL-2 addiction relies on the sequestration of pro-death proteins like BIM. Disrupting BCL-2:BIM complex by BCL-2 inhibitors can trigger cell death. MDM2 inhibitor APG-115 reprograms cell cycle, apoptosis and immune/inflammatory pathways to re-sensitize cells to BCL-2 inhibitor.DisclosuresDeng: Ascentage Pharma Group: Employment. Yin: Ascentage Pharma Group: Employment. Mao: Ascentage Pharma Group: ...
Source: Blood - Category: Hematology Authors: Tags: 603. Oncogenes and Tumor Suppressors: Poster II Source Type: research
Abstract c-Met and VEGFR-2 have attracted interest as novel targets for treatment of various cancers. Aiming to develop potent dual c-Met and VEGFR-2 inhibitors, a series of pyrrolo[1,2-f][1,2,4]triazine derivatives were designed and synthesized. The majority of target compounds exhibited potent antiproliferative effect against c-Met addictive cancer cell lines with IC50 values ranged from 1.2 to 24.6 nM, especially 27a. In-depth studies demonstrated 27a has great selectivity to c-Met and VEGFR-2, and potent inhibitory activity against them (IC50 of 2.3 ± 0.1 nM and 5.0 ± 0.5 nM). Furth...
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Tags: Eur J Med Chem Source Type: research
Authors: Li T, Le A Abstract KEY POINTS: Dysregulation of the TCA cycle and glutamine addiction are characteristic features of glutamine metabolism in cancers. Targeting glutamine metabolism in cancer includes inhibition of glutaminolysis by glutaminase inhibitors, combination therapy, knockdown of c-MYC, inhibition of GDH, depletion of glutamine supply, inhibition of glutamine uptake, and usage of glutamine analogs. Transaminase upregulation and targeting amino acid synthesis have potential for cancer therapy. PMID: 29946773 [PubMed - in process]
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Abstract Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to eliminate addiction in order to maintain a normal life and prevent or reduce relapse. In recent years, there have been some novel and significant findings on the off-label usage of naltrexone. Within a specific dosage window, LDN can act as an immunomodulator in multiple autoimmune diseases and malignant tumors as well as alleviate the symptoms of some mental disorders. The results of increasing studies indicate that LDN exerts its immunoregulatory activity by binding to op...
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Tags: Int Immunopharmacol Source Type: research
Contributor : Andreas EgerSeries Type : Expression profiling by arrayOrganism : Homo sapiensComplex three-dimensional (3D) in vitro model systems that recapitulate human tumor biology are essential to better understand the pathophysiology of the disease and to aid in the discovery of novel anti-cancer therapies. 3D organotypic cultures exhibit intercellula communication, nutrient and oxygen gradients, and cell polarity that is lacking in traditional two-dimensional (2D) monolayer cultures. In the present study, we could demonstrate that 2D and 3D cancer models exhibit different drug sensitivities towards both targeted inhi...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
Loss-of-function mutations in the CBP/CREBBP gene, which encodes a histone acetyltransferase (HAT), are present in a variety of human tumors, including lung, bladder, gastric, and hematopoietic cancers. Consequently, development of a molecular targeting method capable of specifically killing CBP-deficient cancer cells would greatly improve cancer therapy. Functional screening of synthetic-lethal genes in CBP-deficient cancers identified the CBP paralog p300/EP300. Ablation of p300 in CBP-knockout and -deficient cancer cells induced G1/S cell-cycle arrest, followed by apoptosis. Genome-wide gene expression analysis revealed...
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Finding Synthetic Lethal Interactions through Functional Genomics: Poster Presentations - Proffered Abstracts Source Type: research
Purpose of review: The present review introduces recent outstanding progress pertaining to Enhancer of zeste homolog 2 (EZH2), especially regarding its mode of action as a master regulator of chromatin, and provides molecular-based evidence for targeting EZH2 in cancer therapy. We discuss the active development of small molecules targeting the enzymatic activity of EZH2/polycomb repressive complex 2 (PRC2). Recent findings: Genetic, transcriptional, and posttranscriptional dysregulation of EZH2 is frequently observed in many cancer types. EZH2 promotes tumorigenesis by altering the expression of numerous tumor suppressor ...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: INNOVATIVE AGENTS AND TREATMENT MODALITIES: Edited by Ahmad Awada and Steven T. Rosen Source Type: research
More News: Addiction | Cancer | Cancer & Oncology | Cancer Therapy | Science